Mirabegron Teva

Mirabegron, the active ingredient in Mirabegron Teva, is a β3‑adrenergic receptor agonist presented as an oral dosage form for oral use. It is indicated for the management of overactive bladder symptoms such as urinary urgency, frequency and urge incontinence in adults, and is used when these symptoms persist despite behavioral therapy.

GNH USA supplies Mirabegron Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, clinics and procurement teams worldwide, ensuring consistent quality and regulatory compliance across global markets.

Mirabegron is a β3‑adrenergic receptor agonist used to treat overactive bladder, a condition characterized by urinary urgency and frequency.

Overactive bladder: increases bladder capacity and reduces urgency episodes. Urinary urgency: alleviates sudden strong urge to void. Urge urinary incontinence: decreases episodes of involuntary leakage.

Adverse reactions may occur with mirabegron therapy.

Common Side Effects: - Hypertension: elevated blood pressure observed in some patients. - Nasopharyngitis: mild upper respiratory tract infection symptoms. - Urinary tract infection: signs of infection such as dysuria or frequency. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Dry mouth: decreased salivation.

Serious or Rare Side Effects: - Angioedema: swelling of face, lips, or airway requiring immediate medical attention. - Severe hypertension: markedly high blood pressure that may need emergency care. - Urinary retention: difficulty emptying the bladder. - Myocardial infarction: rare occurrence of heart attack. - Acute renal failure: sudden loss of kidney function.

Before initiating mirabegron, clinicians should evaluate patient-specific risk factors. - Blood pressure monitoring: check baseline and periodically during therapy. - Assess urinary retention: watch for signs of incomplete bladder emptying. - Review renal function: adjust use in patients with impaired kidney function. - Caution with uncontrolled hypertension: avoid or use with close supervision. - Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Mirabegron may interact with other medicines affecting its metabolism or therapeutic effect.

Major Interactions (Avoid): - Strong CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): may increase mirabegron exposure. - Antihypertensive agents: mirabegron can reduce their blood‑pressure‑lowering effect. - Concomitant use with antimuscarinics may diminish overall efficacy for bladder control.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may raise plasma levels. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may lower mirabegron concentrations. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may increase risk of hypertension.